Bronchiolitis obliterans

Vaping now more common than smoking among young people – and the risks go beyond lung and brain damage

Retrieved on: 
Thursday, April 25, 2024
Flavor, Nitrosamine, Temperature, Health, Bronchiolitis obliterans, Brain, Herbal cigarette, Learning, Tobacco, Nicotine, Inhalation, Research, Self-control, Cancer, University, Food, Life, Adolescence, Asthma, Diacetyl, Electronic cigarette, World Health Organization, Smoking, Polonium, Fruit, Safety, Chocolate, Cotinine

This echoes research that has found the popularity of vaping among young people in the UK has surged in recent years.

Key Points: 
  • This echoes research that has found the popularity of vaping among young people in the UK has surged in recent years.
  • But vaping comes with many risks to young people, including harm to the lungs and brain.
  • Young people who vape may be more likely to start smoking and find it harder to quit any nicotine use at all.
  • And using vaping products alongside other products containing nicotine, like cigarettes, for example, may be even worse for their health.

Hidden risks

  • There are many less obvious risks to vaping too.
  • The chemicals in vape liquids – including various toxins, heavy metals and possibly even radioactive polonium – may be harmful.
  • This could be because of the specific mix of ingredients different brands put in the vape liquid.
  • Even if a vape liquid is advertised as being nicotine-free, it might still contain chemicals called nitrosamines, which are known to cause cancer.

Is a ban on disposable vapes enough?

  • The forthcoming ban on disposable vapes in England, Scotland and Wales may not be enough to deal with the problem.
  • With more than 400 vape brands already on the market, a more comprehensive approach is needed.


Amira Guirguis does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

Retrieved on: 
Tuesday, March 5, 2024
Infection, MCM, NIAID, NIH, ARS, TEL, FDA, SPHK2, Food, Acute radiation syndrome, RNCP, Bronchiolitis obliterans, Radiation, Mustard gas, HHS, Administration, COVID-19, Chem, ASPR, CCRP, Fibrosis, Acute respiratory distress syndrome, Development, White lung, Opaganib, Pharmaceutical industry

The overall evaluation will also include assessment of opaganib's efficacy against sub-chronic fibrosis and acute respiratory distress syndrome (ARDS) resulting from Sulfur Mustard exposure.

Key Points: 
  • The overall evaluation will also include assessment of opaganib's efficacy against sub-chronic fibrosis and acute respiratory distress syndrome (ARDS) resulting from Sulfur Mustard exposure.
  • "With the alarming increase in global geo-political instability, the opportunity to evaluate opaganib as a potential vital protective agent against chemical attack is inspiring.
  • "Opaganib is the first selective sphingosine kinase-2 (SPHK2) inhibitor investigational drug targeting sphingolipid metabolism to be evaluated as a chemical countermeasure.
  • Opaganib, a novel oral, small molecule pill with a five-year shelf-life, is easy to administer and distribute for use against potential chemical weapon attack, if approved by the FDA.

Breath Therapeutics, a Zambon company, initiates BOSTON-3 and BOSTON-4, two additional clinical studies for the treatment of bronchiolitis obliterans syndrome (BOS)

Retrieved on: 
Thursday, February 20, 2020
Pharmaceutical, Health, Clinical trials, Medical specialties, Medicine, RTT, Clinical medicine, Industrial hygiene, Transplantation medicine, Bronchiolitis obliterans, Bronchiolitis, Hematopoietic stem cell transplantation, Zambon, Zambon S.p.A., Breath Therapeutics, a Zambon company

Anne Bergeron, MD, PhD, Prof, Hpital Saint Louis, Paris said, Bronchiolitis obliterans syndrome is the primary noninfectious pulmonary complication in patients who undergo allogeneic HSCT.

Key Points: 
  • Anne Bergeron, MD, PhD, Prof, Hpital Saint Louis, Paris said, Bronchiolitis obliterans syndrome is the primary noninfectious pulmonary complication in patients who undergo allogeneic HSCT.
  • Noreen R. Henig, MD, Chief Medical Officer at Breath Therapeutics, a Zambon company, stated, "We are pleased with the significant advancements weve achieved in the development of LCsAi for the treatment of BOS.
  • The robust BOSTON development plan will provide essential information about the safety and efficacy of L-CsA-i for most patients suffering from BOS.
  • LCsAi is advancing in clinical trials for the treatment of BOS, a rare and devastating lung disease with no currently approved treatments.

Bronchiolitis Obliterans Syndrome Pipeline Insight Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 17, 2019
Health, Pharmaceutical, RTT, Health, Medical specialties, Occupational diseases, Medicine, Bronchiolitis obliterans, Industrial hygiene, Bronchiolitis, Bronchiole

The "Bronchiolitis Obliterans Syndrome Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bronchiolitis Obliterans Syndrome Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Bronchiolitis Obliterans Syndrome (BOS) - Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Bronchiolitis Obliterans Syndrome (BOS) pipeline landscape is provided which includes the disease overview and Bronchiolitis Obliterans Syndrome (BOS) treatment guidelines.
  • The assessment part of the report embraces, in depth Bronchiolitis Obliterans Syndrome (BOS) commercial assessment and clinical assessment of the pipeline products under development.